Global Autoantibody Kit Market Size, Share & Trends Report by Product (Kits (Serological Kits, Immunoglobin Kits, and Lateral Flow Assay Kits), Chemical and reagents and Consumables), By Indication (Cardiovascular Diseases, Autoimmune Diseases, Infectious Diseases, Oncology, Endocrine Diseases, Diabetes, and Others), and by End-User (Hospitals, Diagnostic Laboratories Homecare Settings, Academic & Research Institutes and Biopharmaceutical companies) Forecast (2022-2028)

The global autoantibody kit is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Autoantibodies are antibodies that react with self-antigens. The rise in the prevalence of diabetes is one of the factors driving the demand for the autoantibody kits market. For instance, according to IDF Diabetes Atlas Tenth Edition 2021, approximately 537 million people, between the age of 20-79 years are living with diabetes and the total number is projected to rise to 643 million by 2030, 783 million by 2045. More than 1.2 million children and adults are living with type -1 diabetes and 541 million adults are at an increased risk of developing type -2 diabetes According to IDF, diabetes has caused more than 6.7 million deaths globally.

Moreover, innovative product launches are anticipated to drive the growth of the global autoantibody kit market. For instance, in May 2021, Defense Research and Development Organization (DRDO) in association with Vanguard Diagnostics Pvt Ltd had developed DIPCOVAN, an anti-body detection kit in New Delhi. Dipcovan is an IgG antibody that possesses the potential to detect nucleocapsid proteins of the SARS-COV-2 virus with a sensitivity of 97% and specificity of 99%. Moreover, the dipcovan had been approved by the Indian Council of Medical Research (ICMR) in April 2021. Further, in May 2021, the product had received the approval from Drugs Controller General of India, Central Drugs Standard Organization, Ministry of Health, and Family Welfare to manufacture for sale and distribution.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Product
  • By Indication
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Abbot Laboratories, Cipla Inc., Bio-Rad Laboratories Inc, and Thermo Fisher Scientific Inc among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Autoantibody Kit Market Report by Segment

By Product

• Kits (Serological Kits, Immunoglobin Kits, and Lateral Flow Assay Kits)
• Chemicals & Reagents
• Consumables

By Indication

• Autoimmune Diseases
• Cardiovascular Diseases
• Diabetes
• Infectious Diseases
• Oncology
• Endocrine Diseases
• Others

By End-User

• Hospitals
• Diagnostic Laboratories
• Homecare Settings
• Academics and Research Institute
• Biopharmaceutical Companies

Global Autoantibody Kit Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa